Defence And Security Tenders

Conclusion not Excluding Drug Discount Agreement. According to Section 130A Paragraph 8 Sgb V through an Open House Model for the Active Ingredient Flecainide (Atc Code According to Who: C01bc04)

Open House Biologics Discount Agreements 2023-27 - Eculizumab

Drug Contracts with Accession Option

Conclusion not Excluding Drug Discount Agreement. According to Section 130A Paragraph 8 Sgb V through an Open House Model for the Active Ingredient Glatiramer Acetate (Atc Code According to Who: L03ax...

Conclusion not Excluding Drug Discount Agreement. According to Section 130A Paragraph 8 Sgb V through an Open House Model for the Active Ingredient Pipamperone (Atc Code According to Who: N05ad05)

Conclusion not Excluding Drug Discount Agreement. According to Section 130A Paragraph 8 Sgb V by Means of an Open House Model for the Active Ingredient Leuprorelin (Atc Code According to Who: L02ae02)

Conclusion not Excluding Drug Discount Agreement. According to Section 130A Paragraph 8 Sgb V through an Open House Model for the Active Ingredient Tocilizumab (Atc Code According to Who: L04ac07)

Conclusion of Non-Exclusive Discount Agreements in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredients Mentioned with the Possibility of Conclusion Within the Framework of the So-Called Open House Procedure.

Open House Procedure: Tafluprost (S01ee05)

Open House Procedure: Ciclosporin (S01xa18)